Last updated on April 2019

AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia
  • Age: Between 18 - 85 Years
  • Gender: Male or Female

INCLUSION CRITERIA: -Pathologically documented, multiple myeloma relapsed or refractory disease after at least 2 lines of therapy, -Must be willing and able to undergo bone marrow biopsy at screening, -Measurable disease per the IMWG response criteria, -Eastern Cooperative Oncology Group (ECOG) performance status of 2, -Satisfactory hematological function without transfusion or growth factor support, -Subjects should not have received platelet transfusions for at least 1 week prior to screening, -Hemoglobin > 8 g/dL, -Subjects may receive RBC transfusions or receive supportive care), -Other Inclusion Criteria May Apply.

EXCLUSION CRITERIA: -Previously received an allogeneic stem cell transplant within 6 months OR having received immunosuppressive therapy within the last three months OR having signs or symptoms of acute or chronic graft-versus-host disease, -Autologous stem cell transplant less than 90 days prior to study day 1, -Multiple myeloma with IgM subtype, -POEMS syndrome, -Existing plasma cell leukemia, -Waldenstrom's macroglobulinemia, -Amyloidosis, -Glucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 7 days prior to starting treatment, -Topical or inhaled corticosteroids are permitted, -Infection requiring intravenous anti-infective treatments within 1 week of study enrollment (day 1), -Other exclusion Criteria May Apply.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.